Skip to main content

Table 2 Characteristics of included programs

From: Misoprostol for postpartum hemorrhage prevention at home birth: an integrative review of global implementation experience to date

Country (* indicates peer-reviewed reference)

Design and scope

Home birth rate (for region or program area, where available; **indicates national rate)

Number of women enrolled (for “studies,” number reflects intervention group only)

Number of women taking misoprostol (aindicates overall; bindicates number from postpartum subsample)

Administration method(s)

Afghanistan [24]*

Study using nonrandomized experimental control design in 2 districts

80.1%

2039

13501

Self

Bangladesh [33]

Operations research project in 6 districts

87%

118,594 enrolled; 77,337 delivered, of whom 53,897 received CDK2

46,561a 1893b

Self and TBA

Bangladesh [14]*3

Study using quasi-experimental design in 2 districts

85%**

1009

884

CHW

Bangladesh [34]

Pilot project in 1 district

85%**

19,497

9228

Self

Ethiopia [13]*

Study using quasi-experimental design in 1 area

97%

500

485

TBA

Gambia [35]*

Study using randomized controlled design in 1 district

72%

630

630

TBA

Ghana [36]

Pilot project in 4 districts

37.5%

5345

1261b

Self

India [22]*

Study using randomized controlled design in 1 district

45.2%

812

809

SBA

Indonesia [37]

Study using nonrandomized experimental design in 2 districts

48%

1322

999

Self

Kenya [38]

Pilot project in 2 districts

38.7%

3844

1084b

Self and SBA

Mozambique [39]

Operations research project in 4 districts, with each of 3 sites using a different distribution strategy: 1) late ANC only, 2) TBA at birth, 3) a combination of late ANC and TBA at birth

35.3%

11,927

4781b

Self and/or TBA

Nepal [23]*

Operations research project in 1 district

89.1%

18,761

13,969a 435b

Self

Nigeria [40]

Operations research project in 1 state

95%

1875

1421b

TBA

Pakistan [15]*

Study using randomized controlled design in 1 province

65%**

534

533

TBA

Pakistan [41]*4

Study using quasi-experimental design in 2 districts

61%

872

678

TBA

Tanzania [42]

Operations research project in 4 districts

30.8%

12,511

1826b

Self

Zambia [43]

Pilot project in 5 districts

59.9%

5574

233b

Self

Zambia [44]

Pilot project in 10 districts

71% (for rural areas)**

31,315

Not reported

Self and TBA

  1. 1 Administration Before Birth and Adverse Maternal Outcomes were reported for all 1421 women in the intervention group who took misoprostol, regardless of the place of delivery, but for consistency with other studies and programs (and because there was no indication to the contrary), we have assumed, particularly for the adverse outcomes reported in Table 6, that any such outcomes occurred only in those 1350 women taking misoprostol for home births.
  2. 2 Misoprostol included in CDK. The kits used by these programs included gloves, soap, a blood loss measurement mat [31, 32, 45] and other materials recommended for use by women who delivered at home.
  3. 3 Dose of misoprostol used was 400 μg (two tablets).
  4. 4 Misoprostol 600 μg was included in CDK.